Author

S. Y. Byun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2

Frequent Co-Authors

D. Shum· 2 shared I. Choi· 2 shared M. Ko· 2 shared A. Ianevski· 1 shared A. L. P. H. d'Alexandry d'Orengiani· 1 shared D. Kainov· 1 shared J. Lee· 1 shared J.-Y. Min· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. Shum

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivMar 20, 2020

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

S. Jeon, M. Ko, J. Lee…·S. Kim

This study screens 48 FDA-approved drugs for antiviral efficacy against SARS-CoV-2 and identifies 24 drugs with IC50 values between 0.1 M and 10 M, including niclosamide and ciclesonide.

DOI 10.1128/aac.00819-20

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologybioRxivFeb 25, 2020

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19

M. Ko, S. Y. Chang, S. Y. Byun…·M. P. Windisch

The paper screens FDA-approved drugs against a MERS-CoV isolate to identify potential therapies for COVID-19, finding several drugs with therapeutic indexes >6 and synergistic combinations.

DOI 10.3390/v13040651

experimental assaydrug response / drug discovery

𝕏 PostBluesky